Clinical and prognostic analysis of the expression of PD-L1 and COX‑2

Soltanova Irada Fakhraddinkyzy

In modern oncology, the determination of PD-L1and COX-2 in the tumor tissue is one of the promising areas of research that allow you to correctly and adequately make a plan for further treatment of the patient and assess the prognosis of the disease. Determination of the expression level of the PDL-1 molecule and COX-2 is considered as a potential biomarker for predicting the effectiveness and duration of treatment of malignant neoplasms. The lesion of the lymph nodes in cervical cancer is one of the main risk factors for the dissemination of the disease. Metastases in the pelvic lymph nodes are associated with a decrease in the 5-year survival rate of patients from 85% to 53%. From this position, due to the expansion of the opportunities of adjuvant therapy in this category of patients, the study of the receptor profile (PD-L1, COX-2) of tumor cells is of particular relevance. Interpretation of the results of immunohistochemical staining of cervical cancer with antibodies to PD-L1 and COX-2 in a cohort of patients with lymph node metastases (N1) revealed the presence of certain regularities between the expression of PD-L1 and COX-2 and clinical prognostic parameters.

Keywords:cervical cancer, programmed death, ligand, cyclooxygenase, lymph nodes, oncology.